Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Discussing treatment on a global scale: creating a worldwide understanding
Marginalized and high-risk multiple myeloma patients: how to address this issue
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?